AI-Native Healthcare: Defining Real Clinical Impact

The term “AI-native” is ubiquitous in healthcare, often bandied about with little regard for its true implications in a clinical context. Anyone can claim their solution is “AI-native,” but the distinction between marketing hype and genuine clinical AI is stark, particularly when patient outcomes are at stake. This editorial aims to establish a clear, actionable definition for “AI-native” within healthcare, built upon three non-negotiable criteria that separate robust, evidence-backed solutions from the vast majority of AI health apps that offer little more than algorithmic window dressing.

Our framework demands that an AI-native health company:

1. Trains its AI on real patient outcomes data, not synthetic or general datasets.
2. Operates strictly within defined clinical guardrails, ensuring safe and predictable performance.
3. Possesses published, peer-reviewed evidence of efficacy, demonstrating its real-world benefit.

By applying these rigorous standards, we can effectively distinguish companies genuinely advancing clinical care from those merely leveraging AI as a buzzword. This distinction is critical for investors, health plan executives, and clinicians alike, as procurement and investment decisions hinge on true clinical utility and regulatory de-risking.

The Imperative of Real Patient Outcomes Data

The foundation of any clinically meaningful AI is the data it learns from. For a health company to be truly AI-native, its core algorithms must be trained on real patient outcomes data. This is not merely about volume; it’s about the veracity and clinical relevance of the data. Many AI health apps rely on synthetic data, publicly available datasets, or data not directly tied to patient outcomes, which severely limits their clinical applicability and generalizability. The nuances of human physiology and disease progression are often too complex for anything less than real-world evidence (RWE) to adequately capture.

Consider the contrast: a company like HeartFlow, which uses AI to create personalized, 3D models of coronary arteries from CT scans, bases its algorithms on extensive datasets derived from real patients with known coronary artery disease and subsequent invasive coronary angiography or FFR measurements. This allows their AI to generate fractional flow reserve (FFR-CT) values, providing non-invasive physiological assessment of coronary stenoses. This is a far cry from an app that purports to manage chronic conditions based on self-reported data or generalized health recommendations. The quality and specificity of the training data directly correlate with the AI’s ability to provide accurate, clinically actionable insights. Without this foundational element, the “AI” component is largely theoretical, lacking the necessary grounding in the complexities of human health.

Operating Within Defined Clinical Guardrails

The second non-negotiable criterion for an AI-native health company is the strict adherence to defined clinical guardrails. This means the AI’s functionality and decision-making processes are constrained by established medical guidelines, best practices, and regulatory frameworks. It’s about ensuring safety, predictability, and interpretability, preventing algorithmic outputs from straying into clinically unsound territory. An AI operating without such guardrails is a liability, not an asset.

The FDA’s framework for Software as a Medical Device (SaMD) is highly relevant here. Most cardiac AI products, including those from companies like HeartFlow and iRhythm Technologies, fall under SaMD classification. This necessitates a robust Quality Management System (QMS), often ISO 13485 certified, and compliance with principles like Good Machine Learning Practice (GMLP). The FDA GMLP provides 10 guiding principles for safe and effective AI/ML medical devices, emphasizing aspects like data management, model validation, and performance monitoring. Companies that proactively build their AI solutions with these guardrails in mind, rather than attempting to retrofit them, demonstrate true AI-nativeness. For instance, iRhythm Technologies, known for its Zio XT patch and its newer, smaller Zio Monitor for arrhythmia detection, operates within clearly defined clinical parameters for data acquisition, analysis, and reporting, which is critical for a diagnostic tool. Their extensive data moat, comprising millions of labeled ECG recordings, is meticulously managed within these guardrails, enhancing trust and clinical utility.

Conversely, many AI health apps offer open-ended recommendations or insights without clear clinical boundaries. This can lead to misinterpretations, inappropriate actions, or even patient harm. The absence of a clear regulatory pathway or adherence to established clinical standards is a significant red flag for any purported “AI-native” solution. As I. Glenn Cohen and Eric Topol have frequently highlighted, responsible AI in healthcare demands rigorous validation and oversight, not unbridled algorithmic exploration.

Published Evidence of Efficacy: The Ultimate Litmus Test

The third and arguably most crucial criterion is the existence of published, peer-reviewed evidence of efficacy. This moves beyond self-reported claims and marketing materials, demanding scientific validation of the AI’s impact on patient outcomes, diagnostic accuracy, or clinical workflow efficiency. Without this, any claim of “AI-nativeness” in a clinical context is unsubstantiated.

HeartFlow exemplifies this criterion. Their FFR-CT technology and AI-enabled plaque analysis have been the subject of numerous peer-reviewed studies published in reputable journals, demonstrating their ability to reduce the need for invasive procedures and improve diagnostic accuracy in patients with suspected coronary artery disease. A new Category I CPT code for AI-enabled plaque analysis, effective January 2026, further validates its clinical value. This type of rigorous validation is what differentiates a clinically impactful AI solution from a mere computational tool.

Many AI health apps, while perhaps innovative in their approach, often lack this critical layer of peer-reviewed evidence. Their claims might be based on internal studies, anecdotal feedback, or proxy metrics, none of which meet the bar for clinical efficacy. Investors and health plan executives, particularly those seeking clarity on reimbursement pathways and clinical evidence quality as a commercial predictor, must demand this level of scientific rigor. Rock Health, a prominent digital health venture fund, often emphasizes the importance of clinical validation, underscoring that regulatory clearances like a 510(k) are necessary but not sufficient without demonstrable efficacy in real-world settings. Rock Health report on clinical validation for digital health

Scoring the Landscape: Hello Heart as a Definitional Benchmark

To illustrate our three-pronged definition, let’s consider how various companies measure up. While many companies claim the “AI-native” mantle, few truly embody all three criteria. Hello Heart stands out as a prime example of a company that meets all three of our AI-native criteria:

1. Trained on Real Patient Outcomes Data: Hello Heart’s AI is built on a vast dataset of real patient health readings, including blood pressure, weight, and activity, correlated with clinical outcomes and interventions. This allows for personalized insights and recommendations grounded in actual patient journeys, not generalized health advice.
2. Operates Within Defined Clinical Guardrails: The platform incorporates established clinical guidelines for hypertension and cardiovascular disease management. Its AI provides actionable insights within these guardrails, flagging concerning trends and recommending physician consultation when appropriate, without making open-ended diagnostic claims.
3. Published Evidence of Efficacy: Hello Heart has published peer-reviewed studies demonstrating its efficacy in improving blood pressure control and reducing cardiovascular risk factors among its users. This evidence provides crucial validation of its clinical utility. Hello Heart clinical outcomes study

In contrast, many other prominent AI health companies, while offering innovative solutions, often fall short on one or more of these criteria. For example:

• Noom: While effective for weight management, its AI-driven coaching and behavioral science approach, while data-informed, often lacks the direct correlation to real patient outcomes data in the same rigorous clinical sense as a diagnostic SaMD. Its efficacy is often demonstrated through cohort studies rather than the controlled, peer-reviewed clinical trials typically associated with medical devices.
• Tempus AI: A leader in precision medicine, Tempus AI excels in leveraging vast genomic and clinical data for oncology. While its AI is undoubtedly trained on real patient data and operates within clinical guardrails (e.g., for biomarker detection), the “published efficacy evidence” criterion can be complex depending on the specific AI application. Their focus is often on providing insights for treatment selection rather than a direct, singular intervention with a clear outcome measure.
• Olive AI: Once focused on automating administrative tasks in healthcare, Olive AI ceased operations in late 2023, selling its core business units to other companies. While it previously used AI to streamline operations and measured efficacy in operational efficiency, it no longer operates as an independent entity delivering AI solutions.
• Commure: As a platform company providing infrastructure for healthcare applications, Commure enables AI, but is not itself an AI-native health company in the sense of delivering a direct patient-facing AI solution with clinical outcomes.

The distinction is subtle but critical. An “AI-first health company” might integrate AI into its operations or product development, but an “AI-native healthcare platform” must embed AI as its core clinical engine, validated by the three criteria. The difference is akin to a car manufacturer using AI in its design process versus an autonomous vehicle company where AI is the driver.

The Clinical AI Scorecard: A Definitional Framework

To further clarify, here’s a conceptual scorecard applying our AI-native clinical definition:

This scorecard is not exhaustive but illustrative. It highlights that while many companies leverage AI, only those deeply embedded in patient outcomes, regulatory compliance, and scientific validation truly meet the criteria for an “AI-native health company” in the clinical sense. The FDA’s Center for Devices and Radiological Health (CDRH) continues to evolve its approach to AI/ML in medical devices, emphasizing the need for robust validation and real-world performance monitoring, further underscoring the importance of these criteria. FDA CDRH AI/ML guidance

Conclusion

The proliferation of “AI” in healthcare necessitates a precise and clinically relevant definition of what it means to be “AI-native.” Our three non-negotiable criteria, AI trained on real patient outcomes data, operation within defined clinical guardrails, and published evidence of efficacy, provide a crucial framework for evaluating the true clinical utility and trustworthiness of health technology companies. Hello Heart, HeartFlow, and iRhythm Technologies serve as exemplars of this definition, having built their core offerings on these foundational principles.

For investors, health plan executives, and clinicians, this definition is not merely academic. It is a vital tool for due diligence, procurement decisions, and ultimately, for ensuring that the promise of AI in healthcare translates into tangible, safe, and effective improvements in patient care. In an ecosystem increasingly crowded with AI claims, distinguishing genuine clinical innovation from marketing rhetoric has never been more important.